<DOC>
	<DOCNO>NCT00262132</DOCNO>
	<brief_summary>Corticosteroids presently drug choice treatment pulmonary sarcoidosis . However , corticosteroid associate many significant side effect . For reason , would beneficial find alternative agent corticosteroid treatment pulmonary sarcoidosis . This study open label trial mycophenolate new onset pulmonary sarcoidosis . Patients candidate study biopsy proven pulmonary sarcoidosis vital capacity FEV1 le 80 % predict . Patients must undergo bronchoscopy diagnosis pulmonary sarcoidosis require , addition , cell obtain bronchoalveolar lavage . If patient diagnose pulmonary sarcoidosis , place initial dose 500mg BID mycophenolate 1 week . If blood count affect dose significant symptom think drug relate , dose escalate 1g BID remain 9 week study ( total study drug therapy time 10 week ) . The patient follow multiple study visit . At visit blood test draw make sure significant side effect mycophenolate . In addition , patient history physical perform evaluate clinical state sarcoidosis detect mycophenolate side effect . On completion 10 week mycophenolate therapy , patient undergo second bronchoscopy bronchoalveolar lavage obtain cell analysis . The patient evaluate spirometry , measurement shortness breath ( dyspnea ) , quality life scale ( SF36 ) serial visit study . The primary endpoint study improve , unchanged bad FVC . It hop pilot study suggest mycophenolate reasonable treatment option new onset pulmonary sarcoidosis .</brief_summary>
	<brief_title>Mycophenolate Pulmonary Sarcoidosis</brief_title>
	<detailed_description />
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Inclusion criterion : New acute pulmonary sarcoidosis define FVC FEV1 le 80 percent predict plus symptom worsen dyspnea , cough , chest pain , wheeze patient without prior history pulmonary sarcoidosis . All patient also require bronchoscopy transbronchial biopsy demonstrate noncaseating granuloma unknown cause . Such patient usually treat acute pulmonary sarcoidosis . The transbronchial biopsy specimen must negative stain mycobacteria fungi . &gt; 18 year age Signing write informed consent form . Exclusion Criteria 1 . Previous history adverse reaction mycophenolate . 2 . Current use another immunosuppressive medication . 3 . History active hepatitis another significant liver disease exception proven presume sarcoidosis liver . 4 . Previous history skin cancer 5 . Active peptic ulcer disease 6 . Pregnant and/ lactate female 7 . Serum creatinine &gt; 2.0 mg/dl 8 . Serum bilirubin &gt; 3.0 mg/dl 9 . WBC &lt; 4,000/cu mm3 10 . Has demonstrate noncompliance past 11 . Current alcohol drug abuse 12 . Evidence significant sarcoidosis extrapulmonary organ require therapy mycophenolate dos could taper pulmonary sarcoidosis stable improve . 13 . History previous severe digestive system disease 14 . Patients take azathioprine 15 . Patients take cholestyramine drug affect enterohepatic recirculation 16 . Patients LeschNyhan KelleySeegmiller syndrome 17 . Patients willing receive live vaccine study 18 . Patients phenylketonuria 19 . Patients elevate serum transaminase total bilirubin baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>